Status:
COMPLETED
Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Dyslipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines...
Eligibility Criteria
Inclusion
- Patients who are above target LDL-C and BP who are eligible for treatment
Exclusion
- High liver enzymes
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
1250 Patients enrolled
Trial Details
Trial ID
NCT00330785
Start Date
October 1 2004
End Date
September 1 2005
Last Update
January 27 2021
Active Locations (126)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Calgary, Alberta, Canada, T2N 2T8
2
Pfizer Investigational Site
Calgary, Alberta, Canada, T2N 4N1
3
Pfizer Investigational Site
Calgary, Alberta, Canada, T2S 3C3
4
Pfizer Investigational Site
Calgary, Alberta, Canada, T2X 3X7